This content is Free Access.
Capítulos
- 00:05Título
- 02:02Tissue Preparation
- 03:40Matrix Application
- 05:24MALDI MS Data Acquisition, Processing, and Evaluation
- 12:29Neuropeptide Validation
- 14:18Representative MALDI-MS Results
- 15:55Conclusion
Dopamine replacement pharmacotherapy using L-DOPA is the most commonly used symptomatic treatment of Parkinson’s disease, but is accompanied by side effects including involuntary abnormal movements, termed dyskinesia 1. Here, a protocol for MALDI imaging mass spectrometry is presented that detects changes in rat brain neuropeptide levels related to dyskinesia.
Tags
MALDI Imaging Mass SpectrometryNeuropeptidesParkinson’s DiseaseIMSMolecular SpeciesMALDI MatrixIntact PeptidesProteinsMass AnalyzerMALDI TOF/TOF Mass SpectrometerImaging TechniquesMolecules Of InterestUnsupervised AnalysisMolecular SpecificitySensitivityRegion-specific Distribution ProfilesAnimal Model Parkinson’s DiseaseNeurodegenerative DiseaseDopamine ReplacementL-DOPA-induced Dyskinesias (LID)Opioid Precursor Prodynorphin MRNADynorphin PeptidesNeurotransmission
